

ADAPTOGENICS HEALTH CORP.
FINANCIAL STATEMENTS
FOR THE YEARS ENDED MARCH 31, 2025 AND 2024
(Expressed in Canadian Dollars)

Independent Auditor's Report

To the Shareholders of Adaptogenics Health Corp.

Opinion

We have audited the financial statements of Adaptogenics Health Corp. (the "Company"), which comprise the statements of financial position as at March 31, 2025 and March 31, 2024 and the statements of loss and comprehensive loss, changes in shareholders' equity and cash flows for the years then ended, and notes to the financial statements, including a summary of material accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at March 31, 2025 and March 31, 2024, and its financial performance and its cash flows for the years then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 to the financial statements which describes the material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Other than the matter described in the Material Uncertainty Related to Going Concern section, we have determined there are no key audit matters to be communicated in our report.

Other Information

Management is responsible for the other information. The other information comprises:

- Management's Discussion and Analysis

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information

identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

We obtained the other information prior to the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in this auditor's report. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is Diana Huang.

Crowe Mackay LLP

**Chartered Professional Accountants
Vancouver, Canada
July 9, 2025**

Adaptogenics Health Corp.

Statements of Financial Position

(Stated in Canadian Dollars)

	Notes	March 31, 2025	March 31, 2024
ASSETS			
Current assets			
Cash and cash equivalents		\$ 80,473	\$ 148,990
Amounts receivable		3,357	4,726
Prepaid expenses		575	-
Total current assets		84,405	153,716
TOTAL ASSETS		\$ 84,405	\$ 153,716
LIABILITIES AND EQUITY			
Current liabilities			
Trade and other payables		\$ 26,741	\$ 21,972
TOTAL LIABILITIES		26,741	21,972
Shareholders' equity			
Share capital	5	669,886	669,886
Reserves	6	15,800	15,122
Deficit		(628,022)	(553,264)
Total equity		57,664	131,744
TOTAL LIABILITIES AND EQUITY		\$ 84,405	\$ 153,716
Nature of operations and going concern	1		
Subsequent event	11		
<u>"Daryl Ware-Lane"</u>		<u>"Hani Zabaneh"</u>	
Director		Director	

The accompanying notes are an integral part of these audited financial statements.

Adaptogenics Health Corp.
Statements of Loss and Comprehensive Loss

(Stated in Canadian Dollars)

	Notes	Year-ended March 31,	
		2025	2024
Revenue			
Sales, net of discounts		\$ 100	\$ 1,123
Cost-of-sales		(207)	(713)
Gross Margin		(107)	410
Expenses			
Advertising and promotions		1,737	16,168
Consulting fees		-	520
Filing fees		24,790	20,607
General and administrative		7,026	2,703
Management fees	9	1,000	35,500
Professional fees		44,821	24,033
Share-based payments	6, 9	678	15,122
Total expenses		(80,052)	(114,653)
Loss before other items		(80,159)	(114,243)
Other items			
Write-down of inventory		-	(38,756)
Interest income		5,401	6,050
Loss and comprehensive loss for the year		\$ (74,758)	\$ (146,949)
Weighted average number of common shares outstanding			
Basic		16,397,701	16,397,701
Diluted		16,397,701	16,397,701
Basic and diluted loss per common share		\$ (0.00)	\$ (0.01)

The accompanying notes are an integral part of these audited financial statements.

Adaptogenics Health Corp.

Statements of Cash Flows

(Stated in Canadian Dollars)

	Year-ended	
	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES		
Loss for the year	\$ (74,758)	\$ (146,949)
Item not involving cash:		
Share-based payments	678	15,122
Changes in non-cash working capital items:		
Amounts receivable	1,369	(486)
Prepaid expenses	(575)	36,329
Trade and other payables	4,769	(11,062)
Due to related parties	-	(5,931)
Net cash used in operating activities	(68,517)	(112,977)
Change in cash during the year	(68,517)	(112,977)
Cash and cash equivalents, beginning of the year	148,990	261,967
Cash and cash equivalents, end of the year	\$ 80,473	\$ 148,990
Cash and cash equivalents consists of:		
Cash	\$ 10,473	\$ 18,990
Short-term deposits	70,000	130,000
	\$ 80,473	\$ 148,990
Supplemental Cash Flow Information		
Income taxes paid	\$ -	\$ -
Interest paid (received)	\$ -	\$ -

The accompanying notes are an integral part of these audited financial statements.

Adaptogenics Health Corp.
Statements of Changes in Shareholders' Equity

(Stated in Canadian Dollars)

	Common Shares		Deficit	Reserves	Total
	Number	Amount			
Balance at March 31, 2024	16,397,701	\$ 669,886	\$ (553,264)	\$ 15,122	\$ 131,744
Share-based payments	-	-	-	678	678
Net loss for the year	-	-	(74,758)	-	(74,758)
Balance at March 31, 2025	16,397,701	\$ 669,886	\$ (628,022)	\$ 15,800	\$ 57,664

	Common Shares		Deficit	Reserves	Total
	Number	Amount			
Balance at March 31, 2023	16,397,701	\$ 669,886	\$ (406,315)	\$ -	\$ 263,571
Share-based payments	-	-	-	15,122	15,122
Net loss for the year	-	-	(146,949)	-	(146,949)
Balance at March 31, 2024	16,397,701	\$ 669,886	\$ (553,264)	\$ 15,122	\$ 131,744

The accompanying notes are an integral part of these audited financial statements.

1. NATURE OF OPERATIONS AND GOING CONCERN

Adaptogenics Health Corp. (the “Company”) was incorporated on April 1, 2021 pursuant to the Business Corporations Act (British Columbia). On December 14, 2022, a Prospectus filed by the Company was given final receipt by the British Columbia Securities Commission and on January 9, 2023, the Company’s common shares began trading on the Canadian Securities Exchange (“CSE”). The shares of the Company currently trades under the symbol "ADPT" on the CSE.

These financial statements have been prepared on the assumption that the Company will continue as a going concern and realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation.

The Company is a Canadian-based nutraceutical company focused on the formulation and distribution of functional mushroom products and nutritional supplement alternatives. The Company is in the process of developing product formulations combining functional mushrooms and adaptogenic herbs which are aimed to support holistic health. The Company is committed to growing a presence in North America through a multifaceted distribution strategy to advance the mission of improving and empowering human health and wellness.

The Company’s business may be affected by changes in political and market conditions, such as interest rates, availability of credit, inflation rates, tariffs, changes in laws, and national and international circumstances. Recent geopolitical events and, potential economic global challenges such as the risk of the higher inflation and energy crises, may create further uncertainty and risk with respect to the prospects of the Company’s business.

As at March 31, 2025, the Company had not yet achieved profitable operations, has accumulated losses of \$628,022 since inception, and expects to incur further losses in the development of its business. These events and conditions indicate a material uncertainty that may cast substantial doubt on the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is primarily dependent upon its ability to raise financing from equity markets or borrowings and successful development and launch of its functional mushroom and nutritional supplement alternatives to the market. While the Company has been successful in securing financing in the past, there is no assurance that it will be able to do so in the future. Accordingly, these financial statements do not give effect to adjustments, if any, that would be necessary should the Company be unable to continue as a going concern. If the going concern assumption was not used, then the adjustments required to report the Company’s assets and liabilities on a liquidation basis could be material to these financial statements.

The head office of the Company is located at 1100 – 1111 Melville Street, Vancouver, BC, V6E 3V6.

2. BASIS OF PRESENTATION

a) Statement of compliance and basis of measurement

These audited financial statements, including any comparatives have been prepared using accounting policies in compliance with IFRS Accounting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). These financial statements have been prepared on a historical cost basis, except for financial instruments classified as and measured as at their fair value.

In addition, these audited financial statements have been prepared using the accrual basis of accounting except for cash flow information.

2. BASIS OF PRESENTATION (continued):

b) Statement of compliance and basis of measurement

These audited financial statements of the Company for the year ended March 31, 2025 were reviewed by the Audit Committee and approved and authorized for issue by the Board of Directors on July 9, 2025.

c) Functional currency and presentation currency

The Company's functional and presentation currency is the Canadian dollar.

3. MATERIAL ACCOUNTING POLICIES

a) Cash and cash equivalents

Cash and cash equivalents in the statement of financial position are comprised of cash at banks and on hand, and short-term deposits which are cashable without penalty and are readily convertible into a known amount of cash, and subject to an insignificant risk of change in fair value.

b) Financial instruments

Financial assets classified at fair value through profit or loss ("FVTPL") are initially recorded at fair value and transaction costs are expensed as incurred. Realized and unrealized gains and losses arising from changes in the fair value are recognized in profit or loss.

Financial liabilities classified as at amortized cost are initially recognized at fair value and subsequently measured at amortized cost using the effective interest method.

The following table shows the classification of the Company's financial assets and liabilities under IFRS:

Financial asset or liability	Classification
Cash and cash equivalents	FVTPL
Trade and other payables	Amortized cost

c) Revenue

Revenue is recognized when payment for goods is received from the customer. At that time, transfer of control of the goods is determined by respective shipping terms and certain additional considerations. The Company does not have performance obligations subsequent to delivery on the sale of the goods to the customer and revenues from sale of goods are recognized at a "point-in-time" which is upon passing of control to the customer.

3. MATERIAL ACCOUNTING POLICIES (continued):

d) Share capital

Equity instruments are contracts that give a residual interest in the net assets of the Company. Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Company's common shares, warrants, and stock options are classified as equity instruments. Incremental costs directly attributable to the issue of new common shares, warrants or stock options are shown in equity as a deduction, net of tax, from the proceeds.

The Company has adopted a residual value method with respect to the measurement of shares and warrants issued as private placement units. The residual value method first allocates value to the more easily measurable component based on fair value and then the residual value, if any, to the less easily measurable component. The fair value of the common shares issued in the private placements was determined to be the more easily measurable component, as determined by the closing quoted bid price on the issuance date. The balance, if any, is allocated to the attached warrants. Any fair value attributed to the warrants is recorded as reserves.

e) Loss per common share

Basic loss per share has been calculated using the weighted average number of common shares outstanding during the period.

Diluted loss per share has been calculated using the weighted average number of common shares that would have been outstanding during the respective period had all of the stock options and warrants outstanding at year-end having a dilutive effect been converted into shares at the beginning of the year and the proceeds used to repurchase the Company's common shares at the average market price for the year. If these computations prove to be anti-dilutive, diluted loss per share is the same as basic loss per share.

f) Share-based compensation

The stock option plan allows the Company's employees and consultants to acquire shares of the Company. The fair value of options granted is recognized as a share-based compensation expense with a corresponding increase in equity. Consideration paid on the exercise of stock options is credited to share capital and the fair value of the options is reclassified from reserves to share capital.

The fair value is measured at grant date and each tranche is recognized over the period during which the options vest. The fair value of the options granted is measured using the Black-Scholes option pricing model taking into account the terms and conditions upon which the options were granted. At each financial position reporting date, the amount recognized as an expense is adjusted to reflect the number of stock options that are expected to vest.

Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to profit or loss over the remaining vesting period.

Share-based payments to non-employees are measured at the fair value of the goods or services received or if such fair value is not reliably measurable, at the fair value of the equity instruments issued.

The amounts recorded in reserves for unexercised share options remain in share-based payments reserve upon their expiry or cancellation.

3. MATERIAL ACCOUNTING POLICIES (continued):

g) New standards, interpretations and amendments not yet adopted

As at March 31, 2025, the following accounting standards and amendments are effective for future periods. The Company is in the process of assessing the potential impact upon adoption.

IFRS 18 Presentation and Disclosure in Financial Statements

IFRS 18 introduces three sets of new requirements to give investors more transparent and comparable information about companies' financial performance for better investment decisions.

- Three defined categories for income and expenses - operating, investing and financing - to improve the structure of the income statement, and require all companies to provide new defined subtotals, including operating profit.
- Requirement for companies to disclose explanations of management-defined performance measures (MPMs) that are related to the income statement.
- Enhanced guidance on how to organize information and whether to provide it in the primary financial statements or in the notes.

This new standard is effective for reporting periods beginning on or after January 1, 2027.

4. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS

The Company makes estimates and judgments about the future that affect the reported amounts of assets and liabilities. Estimates and judgments are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual experience may differ from these estimates and assumptions.

The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the year of the change, if the change affects that year only, or in the year of the change and future years, if the change affects both.

Information about critical estimates and judgments in applying accounting policies that have the most significant risk of causing material adjustment to the financial statements are discussed below.

Critical judgments

Critical accounting judgments that management has made in the process of applying accounting policies and that have the most significant effect on the amounts recognized in the financial statements include, but are not limited to the going concern assumption.

5. SHARE CAPITAL

Authorized capital stock: unlimited number of common shares without par value.

During the years ended March 31, 2025 and 2024, there were no common shares issued by the Company.

Upon the Company's shares being listed on the CSE, certain common shares held by the Company's directors were subject to escrow. As at March 31, 2025, the Company had 903,001 common shares (FY2024 – 1,806,001) remaining in escrow which will be fully released over the next 9 months in equal installments.

ADAPTOGENICS HEALTH CORP.
NOTES TO THE FINANCIAL STATEMENTS
(Expressed in Canadian Dollars)
MARCH 31, 2025

6. SHARE-BASED PAYMENTS

Stock Options:

On January 18, 2022, the Company adopted a stock option plan in accordance with the rules and policies of the Canadian Securities Exchange. The terms of any award are determined by the Board, provided that no options may be granted with an exercise price lower than the greater of the closing market price of the Common Shares on (a) the trading day prior to the date of the grant of the stock options, and (b) the date of grant of the stock options, and the term may not exceed 10 years. The aggregate number of securities available for issuance under the plan may not exceed 10% of the number of common shares of the Company issued and outstanding from time to time.

During the year-ended March 31, 2025, there were no stock options granted by the Company.

During the year-ended March 31, 2024, the following stock options were granted by the Company:

- On August 16, 2023, the Company granted 550,000 stock options to certain directors, an officer and consultants at an exercise price of \$0.10. The stock options expire on August 15, 2026 and vest in four graded installments with the first installment of 137,500 of these options vesting immediately upon grant. The Company has recognized \$15,122 for share-based payments for the year-ended ended March 31, 2024.

The fair value of the 550,000 stock options was estimated using the Black-Scholes option pricing model assuming a weighted average risk-free interest rate of 4.80%, a dividend yield of nil, a weighted average expected annual volatility of the Company's share price of 100% and an expected life of 3 years. The fair value of the stock options was \$0.06 per option. The expected volatility assumption is based on the estimated volatility of comparable early-stage companies. The risk-free interest rate is based on yield curves on the Canadian government zero-coupon bonds or Canadian government treasury bills with a remaining term equal to the options' expected life.

The change in stock options issued for the years ended March 31, 2025 and 2024 is as follows:

	Number of options	Exercise price
Balance, March 31, 2023	-	\$ -
Granted	550,000	0.10
Balance, March 31, 2024 and 2025	550,000	\$ 0.10

Stock options exercisable and outstanding as at March 31, 2025 is as follows:

Expiry Date	Number of options	Exercise Price
August 15, 2026	550,000	\$ 0.10

7. FINANCIAL INSTRUMENTS AND RISK FACTORS

The Company determines the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instrument.

The Company's cash and cash equivalents is measured at fair value, under the fair value hierarchy based on level 1 quoted prices in active markets for identical assets or liabilities.

The three levels of the fair value hierarchy are:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and

Level 3 – Inputs that are not based on observable market data.

The fair value of the Company's accounts payable and accrued liabilities approximate their carrying value, which is the amount recorded on the statement of financial position, due to their short-term nature.

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Credit risk

Credit risk is the risk of loss associated with a counterparty's inability to fulfill its payment obligations. The Company believes it has no significant credit risk. Cash and cash equivalents are held at high credit worth financial institutions and are not subject to significant credit risk.

Liquidity risk

The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at March 31, 2025, the Company had a cash and cash equivalents balance of \$80,473 (FY2024 - \$148,990) to settle current liabilities of \$26,741 (FY2024 - \$21,972). The Company expects to fund future liabilities through the issuance of capital stock. See Note 1 for discussion of going concern risk.

Market risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates and commodity and equity prices. The Company is not subject to commodity and equity price risk.

a) Interest rate risk

The Company has cash balances which are not at a significant risk to fluctuating interest rates. The Company's current policy is to invest excess cash in investment-grade short-term deposit certificates issued by its banking institution.

As at March 31, 2025, the Company had \$70,000 (FY2024 - \$130,000) invested in investment-grade short-term deposit certificates earning interest tied to the bank's Prime Interest Rate per annum. The Company is not subject to significant interest rate risk.

ADAPTOGENICS HEALTH CORP.
NOTES TO THE FINANCIAL STATEMENTS
(Expressed in Canadian Dollars)
MARCH 31, 2025

8. CAPITAL MANAGEMENT

The Company manages its capital structure and make adjustments to it, based on the funds available to the Company, in order to support the acquisition, and the development of its business interests. The Board of Directors does not establish quantitative return on capital criteria for management but rather relies on the expertise of the Company's management to sustain future development of the business.

The Company is largely dependent upon external financing to fund activities. In order to fund new business opportunities and pay for administrative costs, the Company will spend its existing working capital and raise additional funds as needed. The Company will continue to assess new business opportunities and seek to acquire new business assets if it determines there are sufficient business opportunities or economic potential and if it has adequate financial resources to do so (see Note 1).

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management during the year ended March 31, 2025. The Company is not subject to externally imposed capital requirements.

9. RELATED PARTY TRANSACTIONS

Related parties and related party transactions impacting the accompanying financial statements are summarized below and include transactions with the following individuals or entities:

Key management personnel:

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of executive and non-executive members of the Company's Board of Directors and corporate officers.

Remuneration attributed to key management personnel can be summarized as follows:

	Year-ended March 31,	
	2025	2024
Management fees	\$ 1,000	\$ 35,500
Share-based payments	277	8,249
Total	\$ 1,277	\$ 43,749

*includes base salaries pursuant to employment or consultancy arrangements and have been recorded in management fees.

- During the year ended March 31, 2025, the Company paid management fees totaling \$nil (FY2024 - \$13,000) to Daryl Ware-Lane, a director and the CEO of the Company.
- During the year ended March 31, 2025, the Company paid management fees totaling \$nil (FY2024 - \$9,000) to Blue Ocean Productions Ltd., a company controlled by a director of the Company.
- During the year ended March 31, 2025, the Company paid management fees totaling \$nil (FY2024 - \$9,000) to Hani Zabaneh, a director of the Company.
- During the year ended March 31, 2025, the Company paid management fees totaling \$1,000 (FY2024- \$4,500) to MJJ Corporate Services Inc., a company controlled by the CFO of the Company.

ADAPTOGENICS HEALTH CORP.
NOTES TO THE FINANCIAL STATEMENTS
(Expressed in Canadian Dollars)
MARCH 31, 2025

10. INCOME TAX

	2025	2024
Net loss for the year	\$ (74,758)	\$ (146,949)
Expected income tax (recovery) – 27%	(20,185)	(39,676)
Permanent difference	183	4,107
Change in unrecognized temporary difference	20,002	35,569
Total income tax expense (recovery)	\$ -	\$ -

As at March 31, 2025, the Company had non-capital losses of approximately \$611,000, if not utilized will expire between 2042 and 2045.

11. SUBSEQUENT EVENT

Subsequent to the year-ended March 31, 2025, an aggregate of 451,500 common shares were released from escrow. The Company has 451,501 common shares remaining in escrow and are scheduled to be released on January 9, 2026.